Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 3, 1996, Pages 344-348

  Ruiz Arguelles G J ^a   Garces Eisele J ^a   Alarcon Segovia D ^b   Ruiz Arguelles A ^a  

^a Laboratorios Clinicos de Puebla   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; APC resistance; Protein C resistance; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; PRIORITY JOURNAL; THROMBOPHILIA;

EID: 0030003945     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199604000-00009     Document Type: Article

References (41)

1. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Alarcón-Segovia D, et al. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thrombosis and the antiphospholipid syndrome. J Rheumatol 1991; 18: 552-558.
2. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Lobato-Mendizábal E, et al. Disturbances in the tissue plasminogen activator/ plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematous. Am J Hematol 1991; 37: 9-13.
3. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Velázquez BM. Serum lipoprotein (a) levels are increased in patients with the antiphospholipid syndrome and might be associated to thrombophila. Clin Appl Thrombosis/Hemostasis 1996 (in press).
4. Alarcón-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989; 16: 762-767.
5. Ruiz-Argüelles A, Vázquez-Prado J, Delezé M, et al. Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies. Am J Hematol 1993; 44: 58-59.
6. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Alarcón-Segovia D. Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol. Acta Haematol 1993; 89: 206-208.
7. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/amithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb Res 1993; 71: 103-107.
8. Ruiz-Argüelles A, Anglés-Cano E, Pérez-Romano B, et al. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am J Hematol 1995; 49: 109-114.
9. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Delezé M, Alarcón-Segovia D. Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of the anticardiolipin antibody with thrombomodulin. J Rheumatol 1989; 16: 381-383.
10. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' antibodies. Blood 1994; 84: 2854-2867.
11. Alarcón-Segovia D. Delezé, M. Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365.
12. Cabiedes J, Cabral AR, Alarcón-Segovia D. Clinical manifestations of the antiphospholipid syndrome in systemic lupus erythematosus patients associate more strongly with anti-beta 2 glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 49: 109.
13. Alarcón-Segovia D, Sánchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-488.
14. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The 'primary' antiphospholipid syndrome. Major clinical and serological features. Medicine 1989; 68: 366-374.
15. Dahlbäck B, Carlsson M, Svensoon PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1994; 90: 1004-1008.
16. Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med 1995; 237: 221-227.
17. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125.
18. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
19. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
20. Pötzsch B, Kawamura H, Preissner KT, et al. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125: 56-65.
21. Key NS. Toward an understanding of the pathophysiologic mechanism of thrombosis in the antiphospholipid syndrome. J Lab Clin Med 1995; 125: 16-17.
22. Cooper PC, Hampton KK, Abusenadah A, et al. Activated protein C resistance in antiphospholipid containing plasma: a possible mechanism of thrombosis. Br J Haematol 1994; 86: 2.
23. Walker ID, Hickman GM, Stevenson C, McCall F. High prevalence of APC resistance in the presence of antiphospholipids. Br J Haematol 1994; 86: 2.
24. Anglés A, Fernández P, Nicolau C, et al. An approach to the significance of activated protein C resistance. Haemostasis 1994; 24: 152.
25. Cumming AM, Tait RC, Fildes S, et al. Development of resitance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-727.
26. Osterud B, Robertsen R, Asvang GB, Thijssen. Resistance to activated protein in women using oral contraceptives. Blood Coag Fibrinol 1994; 5: 853-854.
27. Davies KA, Ireland H, Athanassiou P, et al. Factor V Leiden mutation and venous thrombosis. Lancet 1995; 345: 132-133 (letter).
28. Biousse V, Piette JC, Frances C, et al. Primary antiphospholipid syndrome is not associated with activated protein C resistance caused by factor V Arg 506→Gln mutation. J Rheumatol 1995; 22: 1215 (letter).
29. Cortesse-Hassett A, Bontempo F, Faruki H, et al. Activated protein C resistance (APCr) and factor V Leiden in patients with SLE. Blood 1995; 86-204a (abstract).
30. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
31. Exner T, Papadopoulos G, Koutts. Use of a simplified dilute Russell viper venom time (dRVVT) confirms heterogeneity among lupus anticoagulants. Blood Coag Fibrinol 1990; 1: 259-266
32. Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1289-1290.
33. Koster T, Rosendaal FR, Ronde D, et al. Venous thromboembolism due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
34. Matsuda J, Gohchi K, Tsukamoto M, et al. Resistance to activated protein C in systemic lupus erythematosus with antiphospholipid antibodies. Eur J Haematol 1994; 53: 188-189.
35. Matsuda J, Gotoh M, Gohchi K, et al. Resistance to activated protein C activity of an anti-β2-glycoprotein I antibody in the presence of β2-glycoprotein I. Br J Haematol 1995: 90: 204-206.
36. Dahlbäck B. Resistance to activated protein C. N Engl J Med 1994; 331: 129-130.
37. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996.
38. de Groot PG, Derksen RHWN. Protein C pathway, antiphospholipid antibodies and thrombosis. Lupus 1994; 3: 229-233.
39. Halbmayer WM, Haushofer A, Schon R, Fischer M. Influence of lupus anticoagulants on a commercially available kit for APC-resistance. Thromb Haemost 1994; 72: 645-646.
40. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
41. Dahlbäck B. Activated protein C resistance caused by a factor V gene mutation as a major basis for thrombosis. Rev Iberoamer Thromb Hemost 1995; 8: 49-50.